clofutriben

Small molecule

Phase 2topline reported

Evidence outlook

Type 2 Diabetes: topline reported 2026-06-08

The sponsor reported topline results on 2026-06-08 (Phase 2 study NCT02372578 in type 2 diabetes: HbA1c, glucose and total cholesterol reduced versus placebo at 6 weeks). The announcement is listed under Regulatory events.

Also in development:Cushing's Syndrome · Phase 2

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 2 (4)
Cushing's Syndrome
NCT05307328 · Sparrow Pharmaceuticals
2022-09-01 – 2025-08-01 · Cushing's Syndrome I, Cushing Disease Due to Increased ACTH Secretion, Cortisol Excess, Cortisol; Hypersecretion, Cortisol Overproduction, Ectopic ACTH Secretion
What this study did
NCT05436639 · Sparrow Pharmaceuticals
2023-07-01 – 2025-02-18 · Autonomous Cortisol Secretion (ACS), ACTH-Independent Cushing Syndrome, ACTH-Independent Adrenal Cushing Syndrome, Somatic
What this study did
Type 2 Diabetes
Other / comorbidity
NCT05436652 · Sparrow Pharmaceuticals
2022-07-22 – 2025-04-25 · Polymyalgia Rheumatica
What this study did
Phase 1 (4)
Type 2 Diabetes
Other / comorbidity
NCT07227922 · Sparrow Pharmaceuticals
2025-11-30 – 2026-07-01 · Moderate Renal Impairment
What this study did
NCT07226635 · Sparrow Pharmaceuticals
2025-10-03 – 2025-12-16 · Healthy Participants
What this study did
NCT06281236 · Sparrow Pharmaceuticals
2022-02-22 – 2025-04-25 · Polymyalgia Rheumatica
What this study did

Competitive landscape

1 other tracked programme targets this mechanism, 1 of them ahead of this one.

This drug's own stage for Cushing's Syndrome: Phase 2. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Clofutriben: this drugPhase 2Small molecule11-beta-HSD1not yet gradedNo reviewed efficacy summary in this indication
Mifepristone (Korlym)ApprovedSmall moleculeProgesterone receptor; Glucocorticoid receptorWeak signalNo reviewed efficacy summary in this indication
Relacorilant (Lifyorli)Phase 3Small moleculeGlucocorticoid receptorPartial signal
NCT04308590: Change in Average 24-hour SBP (Baseline and Week 22): Relacorilant -5.56 mm Hg (95% CI -10.459 to -0.659) vs Placebo -2.89 mm Hg (95% CI -6.794 to 1.006) missed
Emestedastat (Xanamem)
Phase 2/3(overall)
Small molecule11-beta-HSD1
Partial signal(overall)
No reviewed efficacy summary in this indication

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow clofutriben to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
December 2027 (1)
Phase 2Type 2 DiabetesRecruiting
Est. primary completion 2027-12-31 · NCT07296484 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

8 June 2026Topline resultPhase 2 study NCT02372578 in type 2 diabetes: HbA1c, glucose and total cholesterol reduced versus placebo at 6 weeks
Sparrow Pharmaceuticals · Source ↗